Profile data is unavailable for this security.
About the company
Nanjing Vazyme Biotech Co Ltd is China-based company principally engaged in life sciences, in vitro diagnostics, and biopharmaceuticals. Its products and services cover basic research reagents, high-throughput sequencing reagents, diagnostic raw materials, laboratory consumables and instruments, pharmaceutical R&D reagents, vaccine evaluation reagents and raw materials, etc. The company's products are mainly used in scientific research, high-throughput sequencing, molecular diagnostics, in vitro diagnostics, pharmaceutical, vaccine research and development, animal husbandry, and animal quarantine. The Company mainly conducts its business in the domestic and overseas markets.
- Revenue in CNY (TTM)1.34bn
- Net income in CNY-29.64m
- Incorporated2012
- Employees2.87k
- LocationNanjing Vazyme Biotech Co Ltd1-6F, East Section, Building C1-2Hongfeng Science and Technology ParkKechuang Road, Economic and TechnologicaNANJING 210033ChinaCHN
- Phone+86 2 585771179
- Fax+86 2 585771171
- Websitehttps://www.vazyme.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zhejiang Ausun Pharmaceutical Co Ltd | 751.12m | 184.84m | 7.97bn | 1.22k | 42.83 | 3.40 | -- | 10.61 | 0.2241 | 0.2241 | 0.8963 | 2.83 | 0.2472 | 0.9248 | 3.00 | 616,180.10 | 6.08 | 8.91 | 7.77 | 12.10 | 51.51 | 53.44 | 24.61 | 27.68 | 2.17 | -- | 0.1383 | 27.35 | -2.63 | 20.90 | -18.55 | 29.68 | 17.53 | 43.79 |
| Guangxi Wuzhou Zhongheng Group Co Ltd | 2.29bn | -363.56m | 8.06bn | 2.97k | -- | 1.39 | -- | 3.51 | -0.1112 | -0.1112 | 0.7189 | 1.82 | 0.204 | 2.09 | 3.30 | 771,487.60 | -4.90 | -0.1745 | -7.79 | -0.2739 | 34.13 | 64.36 | -24.05 | -0.6631 | 2.01 | -5.26 | 0.2563 | 69.54 | -26.67 | -9.85 | -547.14 | -- | 4.41 | -- |
| Changchun BCHT Biotechnology Co | 677.51m | -170.53m | 8.07bn | 1.27k | -- | 2.04 | -- | 11.92 | -0.4124 | -0.4124 | 1.64 | 9.57 | 0.1288 | 0.7183 | 0.4756 | 531,801.10 | -3.24 | 8.14 | -4.12 | 10.19 | 77.22 | 85.58 | -25.17 | 23.29 | 1.20 | -8.89 | 0.0696 | 14.91 | -32.64 | 4.73 | -53.67 | 0.9824 | 33.40 | -- |
| Sichuan Huiyu Pharmaceutical Co Ltd | 984.29m | 47.23m | 8.13bn | 1.38k | 172.20 | 2.18 | -- | 8.26 | 0.1115 | 0.1115 | 2.32 | 8.81 | 0.1983 | 0.9536 | 14.36 | 712,220.30 | 0.8073 | 8.62 | 1.04 | 10.46 | 80.54 | 88.41 | 4.07 | 22.26 | 2.63 | -- | 0.1185 | 24.48 | 18.05 | 9.13 | 132.78 | 12.96 | 3.11 | -- |
| Jiangsu Kanion Pharmaceutical Co., Ltd. | 3.13bn | 234.36m | 8.16bn | 6.13k | 34.84 | 1.73 | -- | 2.61 | 0.4136 | 0.4136 | 5.50 | 8.33 | 0.459 | 2.03 | 5.49 | 510,570.90 | 3.29 | 5.72 | 4.42 | 8.14 | 67.90 | 72.85 | 7.18 | 9.42 | 1.73 | 47.38 | 0.0006 | 18.39 | -19.86 | -3.11 | -15.58 | -5.02 | -0.5518 | -- |
| Nanjing Vazyme Biotech Co Ltd | 1.34bn | -29.64m | 8.26bn | 2.87k | -- | 2.15 | -- | 6.15 | -0.0817 | -0.0817 | 3.98 | 9.66 | 0.2715 | 1.10 | 2.75 | 468,919.20 | -0.6649 | 9.69 | -0.8034 | 11.88 | 68.89 | 69.81 | -2.45 | 20.70 | 3.34 | -- | 0.1832 | 35.88 | 7.15 | 38.71 | 74.50 | -- | 30.38 | -- |
| Frontier Biotechnologies Inc | 141.20m | -167.73m | 8.47bn | 302.00 | -- | 8.62 | -- | 59.95 | -0.4478 | -0.4478 | 0.377 | 2.62 | 0.0775 | 1.78 | 2.74 | 467,559.50 | -9.21 | -12.65 | -12.08 | -14.50 | 32.51 | 18.59 | -118.79 | -333.96 | 2.58 | -- | 0.3472 | -- | 13.32 | 44.07 | 38.78 | -- | -35.01 | -- |
| GuangYuYuan Chinese Herbal Medicn Co Ltd | 1.39bn | 82.37m | 8.68bn | 1.74k | 105.35 | 5.26 | -- | 6.25 | 0.1683 | 0.1683 | 2.84 | 3.37 | 0.5711 | 0.6215 | 4.13 | 800,359.30 | 3.51 | -2.57 | 5.10 | -3.94 | 66.36 | 68.69 | 6.15 | -6.95 | 1.16 | 17.91 | 0.0336 | -- | -4.87 | 0.071 | -17.35 | -10.56 | -36.84 | -- |
Data as of Feb 13 2026. Currency figures normalised to Nanjing Vazyme Biotech Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
3.25%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Harvest Fund Management Co., Ltd.as of 30 Jun 2025 | 3.36m | 0.85% |
| China Southern Asset Management Co., Ltd.as of 30 Jun 2025 | 1.66m | 0.42% |
| China Asset Management Co., Ltd.as of 30 Jun 2025 | 1.58m | 0.40% |
| Bosera Asset Management Co., Ltd.as of 30 Jun 2025 | 1.28m | 0.32% |
| Penghua Fund Management Co., Ltd.as of 30 Jun 2025 | 1.14m | 0.29% |
| Hongde Fund Management Co., Ltd.as of 30 Jun 2025 | 1.07m | 0.27% |
| The Vanguard Group, Inc.as of 04 Feb 2026 | 951.77k | 0.24% |
| GF Fund Management Co., Ltd.as of 30 Jun 2025 | 709.01k | 0.18% |
| Huisheng Fund Management Co., Ltd.as of 30 Jun 2025 | 605.04k | 0.15% |
| Yinhua Fund Management Co., Ltd.as of 30 Jun 2025 | 562.96k | 0.14% |
More ▼
Data from 30 Jun 2025 - 12 Feb 2026Source: FactSet Research Systems Inc.
